In brief
George Yancopoulos, Regeneron's president and chief scientist, argues that lasting drug innovation comes from a science-led culture that builds many deep capabilities, such as human antibodies, mouse genetics and human genetics, rather than relying on one trick. He says this long-term approach explains why Regeneron has produced six approved drugs from its own labs.
The central tension is between short-term pressures and long-term innovation. Yancopoulos says quarterly numbers and annual price increases distract from the real problem, which he calls a lack of R&D innovation. He argues that fair pricing is affordable when drugs are truly innovative, and that policy should reward long-term research behavior rather than only punishing high prices.</ol>
Questions
Why has Regeneron succeeded when so many antibody companies disappeared?
Yancopoulos says Regeneron stayed independent instead of aiming to be bought out, and its antibody mice were backed by many other technologies. Rivals such as Medarex and Abgenix were mostly antibody companies.
Did Regeneron really undercut Genentech's Lucentis on price with Eylea?
Only slightly, according to Yancopoulos, who says Eylea was just a few dollars cheaper per injection. Its main advantage was trial data showing patients needed half as many eye injections.
Why does Yancopoulos say drug price increases are not the real problem?
He calls them a symptom of an industry that is not producing enough new drugs. He says big companies raise prices because they cannot grow through innovation.
What is the Regeneron Genetics Center and why would a company run one?
It is Regeneron's large DNA sequencing effort, which connects human genetic differences to disease. Yancopoulos says this helps validate drug targets and discover new ones, and he calls it the largest human sequencing operation in the world.
How does Yancopoulos say a company should decide which programs to push forward?
He says Regeneron keeps stacking up evidence from human genetics, mouse models and antibody tests, and pauses programs when the data weakens. It rarely pushes ahead without strong data, which he says is why late-stage failures are rare.
Facts
Stated by the speakers. Each quote matches the transcript, which shows what was said, not that it is true.
As of the interview, Regeneron Pharmaceuticals had six FDA-approved drugs and was described as the third best-performing stock in the S&P 500 over the prior decade.
“The company has developed six FDA-approved drugs so far, and it's the third best-performing stock in the S &P 500 over the past decade.”
0:00:45 · Luke Timmerman · Regeneron performance · 2017
George Yancopoulos said the FDA approved 22 medicines in 2016, of which only eight were first in class.
“Last year, 2016, 22 medicines approved by the FDA. Only eight of them. Only eight of them first in class.”
0:09:04 · George Yancopoulos · FDA approvals · 2016
George Yancopoulos said he and his mentor Fred Alt first proposed making mice that produce human antibodies in 1985.
“it was my mentor Fred Ault and I in 1985 that actually made the first proposal to make these mice that could make human antibodies.”
0:10:25 · George Yancopoulos · Human antibody mice · 1985
Regeneron Pharmaceuticals had an important collaboration with Medarex, a company that also developed human antibody mice.
“And we actually collaborated. We had an important collaboration with Medarex.”
0:10:25 · George Yancopoulos · Antibody collaboration
Yancopoulos said Len Schleifer helped create a business plan for Regeneron to stay independent, unlike other antibody companies that aimed to be acquired.
“he helped create a business plan and structure where we would stay independent. Whereas a lot of these other companies, their goal was to sort of get bought out.”
0:11:12 · George Yancopoulos · Business strategy
Regeneron Pharmaceuticals had two manufacturing plants, one in Rensselaer, New York and one in Limerick, Ireland.
“where we now have two plants, one up at Ronsolier and one in Ireland, in Raheem in Ireland.”
0:17:29 · George Yancopoulos · Manufacturing · 2017
Regeneron Pharmaceuticals announced an initiative to sequence the exomes of the 500,000-person UK Biobank.
“We just recently announced a major initiative where we're going to be sequencing the UK biobank of 500 ,000 people.”
0:28:09 · George Yancopoulos · Genetic sequencing · 2017
Yancopoulos said Regeneron's first drug approval was its IL-1 trap for cold-induced inflammatory syndrome, which he described as an early example of going from a human genetic disease to a blocking biologic.
“Our first drug approval, which is our IL-1 trap or ARKELIST in cold-induced inflammatory syndrome, was perhaps the first example”
0:29:22 · George Yancopoulos · Arcalyst
Yancopoulos said the IL-1 trap produced an 85 percent average improvement in patients with cold-induced inflammatory syndrome.
“85 % average improvement in a horrific disease. That's how you want genes to work.”
0:30:03 · George Yancopoulos · Arcalyst results
Yancopoulos said Regeneron's PCSK9 antibody was the first approved anti-PCSK9 agent for lowering cholesterol, building on gene discoveries by Helen Hobbs and Jonathan Cohen at UT Southwestern.
“where we got the first approved anti-PCSK9 agent for lowering cholesterol”
0:30:03 · George Yancopoulos · PCSK9
Yancopoulos said Regeneron's head-to-head trials showed Eylea could be injected half as often as Lucentis with comparable results.
“We actually showed head to head that we can inject half as frequently and get as good data.”
0:37:01 · George Yancopoulos · Eylea trials
Yancopoulos said the National Eye Institute ran side-by-side studies comparing Eylea with Lucentis and Avastin, and that Eylea beat them by one to two lines on an eye chart.
“the National Eye Institute and the National Institutes of Health did side-by-side studies, which are rarely done”
0:38:09 · George Yancopoulos · Eylea studies
Yancopoulos said Dupixent launched in atopic dermatitis, a field with no other biologics.
“we priced in a brand new space. There was no other biologics for atopidermatitis.”
0:38:57 · George Yancopoulos · Dupixent launch · 2017
Yancopoulos said Dupixent was priced at less than half the average price of psoriasis drugs.
“we price our drug at less than half the price of the average psoriasis drugs just because we think it's the appropriate thing to do.”
0:39:29 · George Yancopoulos · Dupixent pricing · 2017
Yancopoulos said the U.S. invests about $30 billion in the NIH budget and argued it should be at least an order of magnitude larger for basic research.
“It's a little silly from my perspective that we're investing as a nation $30 billion to attack what are arguably some of the most important challenges we have”
0:42:36 · George Yancopoulos · NIH funding
Luke Timmerman said Allergan transferred patents to an Indian tribe with sovereign immunity to prevent generic companies from challenging them in court, to protect a dry eye franchise.
“Allergan comes out with this patent gambit where they transferred over to an Indian tribe with sovereign immunity so that generic companies can't challenge their patents in court.”
0:45:32 · Luke Timmerman · Patent strategy · 2017
Yancopoulos said Nobel Prize winners Michael Brown and Joseph Goldstein, members of Regeneron's board, have worked together since the 1970s.
“Brown and Goldstein, Nobel Prize winners that have been working together since the 70s.”
0:47:28 · George Yancopoulos · Regeneron board · 1970s
Yancopoulos said Regeneron Pharmaceuticals had 250 interns in the summer of the interview, and the head of the Regeneron Genetics Center began as an intern.
“I think that this summer we had 250 interns.”
0:53:10 · George Yancopoulos · Internships · 2017
Yancopoulos said he and Len Schleifer are alumni of the Science Talent Search, which Regeneron sponsors.
“So many of us, including Len and I, are actual alumni of that program.”
0:53:58 · George Yancopoulos · Science Talent Search
Yancopoulos said Pfizer failed in late-stage phase three trials of a PCSK9 drug after spending billions of dollars.
“Pfizer, in a late stage, phase three trials stage after they spent billions, they failed, which shows how hard this business is.”
0:34:31 · George Yancopoulos · PCSK9 competition